Amedeo Smart

Free Medical Literature Service


 

Amedeo

Autoimmune Disorders

  Free Subscription

Articles published in
Ann Neurol
    August 2021
  1. KIMURA K, Lin Y, Yamaguchi H, Sato W, et al
    Th1 - CD11c(+) B cell axis associated with response to plasmapheresis in multiple sclerosis.
    Ann Neurol. 2021 Aug 23. doi: 10.1002/ana.26202.
    >> Share

  2. PAN S, Chan JR
    Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis.
    Ann Neurol. 2021 Aug 17. doi: 10.1002/ana.26196.
    >> Share

  3. KOLB H, Absinta M, Beck ES, Ha SK, et al
    7T MRI Differetiates Remyelinated from Demyelinated Multiple Sclerosis Lesions.
    Ann Neurol. 2021 Aug 14. doi: 10.1002/ana.26194.
    >> Share

  4. TEWKESBURY G, Song JW, Perrone CM
    Magnetic Resonance Imaging of Autoimmune GFAP Astrocytopathy.
    Ann Neurol. 2021 Aug 13. doi: 10.1002/ana.26195.
    >> Share

    July 2021
  5. HANDUNNETTHI L, Knezevic B, Kasela S, Burnham KL, et al
    Genomic insights into myasthenia gravis identify distinct immunological mechanisms in early and late onset disease.
    Ann Neurol. 2021 Jul 19. doi: 10.1002/ana.26169.
    >> Share

  6. METZ I, Gavrilova RH, Weigand SD, Frischer JM, et al
    MRI Correlates of Multiple Sclerosis Immunopathological Patterns.
    Ann Neurol. 2021 Jul 7. doi: 10.1002/ana.26163.
    >> Share

  7. GELIBTER S, Pisa M, Croese T, Finardi A, et al
    Spinal fluid myeloid microvesicles predict disease course in multiple sclerosis.
    Ann Neurol. 2021 Jul 3. doi: 10.1002/ana.26154.
    >> Share

  8. HAUSER SL
    Curing Multiple Sclerosis: How to Know When We're There?
    Ann Neurol. 2021 Jul 2. doi: 10.1002/ana.26155.
    >> Share

    June 2021
  9. ALLEN CM, Ramsamy S, Tarr AW, Tighe PJ, et al
    Guillain-Barre syndrome variant occurring after SARS-CoV-2 vaccination.
    Ann Neurol. 2021 Jun 10. doi: 10.1002/ana.26144.
    >> Share

  10. MARAMMATOM BV, Krishnan P, Paul R, Padmanabhan S, et al
    Guillain-Barre syndrome following ChAdOx1-S/nCoV-19 vaccine.
    Ann Neurol. 2021 Jun 10. doi: 10.1002/ana.26143.
    >> Share

  11. HARTUNG HP
    Neuromyelitis Optica Spectrum Disorder: Therapeutic Innovations and Complex Decision-Making.
    Ann Neurol. 2021;89:1084-1087.
    >> Share

  12. WINGERCHUK DM, Fujihara K, Palace J, Berthele A, et al
    Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.
    Ann Neurol. 2021;89:1088-1098.
    >> Share

    May 2021
  13. OECHTERING J, Schaedelin S, Benkert P, Muller S, et al
    Intrathecal Immunoglobulin M synthesis is an independent biomarker for higher disease activity and severity in multiple sclerosis.
    Ann Neurol. 2021 May 31. doi: 10.1002/ana.26137.
    >> Share

  14. BEUKER C, Wankner MC, Thomas C, Strecker JK, et al
    Characterization of extracranial giant cell arteritis with intracranial involvement and its rapidly progressive subtype.
    Ann Neurol. 2021 May 16. doi: 10.1002/ana.26101.
    >> Share

  15. LANDA J, Guasp M, Miguez-Cabello F, Guimaraes J, et al
    Encephalitis with autoantibodies against the glutamate kainate receptors GluK2.
    Ann Neurol. 2021 May 5. doi: 10.1002/ana.26098.
    >> Share

  16. AKTAS O, Smith MA, Rees WA, Bennett JL, et al
    Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
    Ann Neurol. 2021;89:895-910.
    >> Share

    April 2021
  17. IZUKA S, Kobayashi T, Takahashi Y
    Tongue tremor in systemic lupus erythematosus.
    Ann Neurol. 2021 Apr 21. doi: 10.1002/ana.26088.
    >> Share

  18. COX LM, Maghzi AH, Liu S, Tankou SK, et al
    The Gut Microbiome in Progressive Multiple Sclerosis.
    Ann Neurol. 2021 Apr 19. doi: 10.1002/ana.26084.
    >> Share

  19. MIRO O, Porta-Etessam J, Gonzalez Del Castillo J
    Reply to: "COVID-19 and the Risk of GBS".
    Ann Neurol. 2021;89:846-847.
    >> Share

  20. PETZOLD A
    Reply to "Peripapillary Hyper-Reflective Ovoid Masslike Structures in Astronauts".
    Ann Neurol. 2021;89:849-850.
    >> Share

  21. WOSTYN P, Gibson CR, Mader TH
    Peripapillary Hyper-Reflective Ovoid Mass-Like Structures in Astronauts.
    Ann Neurol. 2021;89:849.
    >> Share

  22. LUCHICCHI A, Hart B, Frigerio I, van Dam AM, et al
    Axon-Myelin Unit Blistering as Early Event in MS Normal Appearing White Matter.
    Ann Neurol. 2021;89:711-725.
    >> Share

    March 2021
  23. VANDEBERGH M, Andlauer TFM, Zhou Y, Mallants K, et al
    Genetic variation in WNT9B increases relapse hazard in multiple sclerosis.
    Ann Neurol. 2021 Mar 11. doi: 10.1002/ana.26061.
    >> Share

  24. NOURBAKHSH B, Cordano C, Asteggiano C, Ruprecht K, et al
    Multiple Sclerosis Is Rare in Epstein-Barr Virus-Seronegative Children with Central Nervous System Inflammatory Demyelination.
    Ann Neurol. 2021 Mar 11. doi: 10.1002/ana.26062.
    >> Share

    February 2021
  25. DE MEO E, Bonacchi R, Moiola L, Colombo B, et al
    Early predictors of 9-year disability in pediatric multiple sclerosis.
    Ann Neurol. 2021 Feb 17. doi: 10.1002/ana.26052.
    >> Share

  26. DUBEY D, Kryzer T, Guo Y, Clarkson B, et al
    LUZP4 autoantibody: A novel germ cell tumor and paraneoplastic biomarker.
    Ann Neurol. 2021 Feb 14. doi: 10.1002/ana.26050.
    >> Share

    January 2021
  27. SORMANI MP, De Rossi N, Schiavetti I, Carmisciano L, et al
    Disease modifying therapies and Covid-19 severity in Multiple Sclerosis.
    Ann Neurol. 2021 Jan 21. doi: 10.1002/ana.26028.
    >> Share

  28. KOAY S, Vichayanrat E, Bremner F, Panicker JN, et al
    Multi-modal Biomarkers Quantify Recovery in Autoimmune Autonomic Ganglionopathy.
    Ann Neurol. 2021 Jan 13. doi: 10.1002/ana.26018.
    >> Share

  29. DE BRUIJN MAAM, Bastiaansen AEM, Mojzisova H, van Sonderen A, et al
    The Antibodies Contributing to focal Epilepsy Signs and symptoms (ACES) score.
    Ann Neurol. 2021 Jan 11. doi: 10.1002/ana.26013.
    >> Share

  30. LEE ST, Lee BJ, Bae JY, Kim YS, et al
    CaV alpha2delta Autoimmune Encephalitis: A Novel Antibody and its Characteristics.
    Ann Neurol. 2021 Jan 7. doi: 10.1002/ana.26017.
    >> Share

  31. RINALDI S
    Coronavirus Disease 2019 and the Risk of Guillain-Barre Syndrome.
    Ann Neurol. 2021 Jan 4. doi: 10.1002/ana.26011.
    >> Share

    December 2020
  32. FRAGIEL M, Miro O, Llorens P, Jimenez S, et al
    Incidence, clinical characteristics, risk factors and outcomes of Guillain-Barre syndrome in patients with Covid-19.
    Ann Neurol. 2020 Dec 9. doi: 10.1002/ana.25987.
    >> Share

    November 2020
  33. THAM M, Frischer JM, Weigand SD, Fitz-Gibbon PD, et al
    Iron heterogeneity in early active multiple sclerosis lesions.
    Ann Neurol. 2020 Nov 27. doi: 10.1002/ana.25974.
    >> Share

  34. FADDA G, Banwell B, Waters P, Marrie RA, et al
    Silent new brain MRI lesions in children with MOG-antibody associated disease.
    Ann Neurol. 2020 Nov 19. doi: 10.1002/ana.25957.
    >> Share

    October 2020
  35. SOTIRCHOS ES, Calabresi PA, Saidha S
    Reply to "Retinal INL thickness in multiple sclerosis: a mere marker of neurodegeneration?"
    Ann Neurol. 2020 Oct 17. doi: 10.1002/ana.25936.
    >> Share

  36. CORDANO C, Yiu HH, Oertel FC, Gelfand JM, et al
    Retinal INL thickness in multiple sclerosis: a mere marker of neurodegeneration?
    Ann Neurol. 2020 Oct 17. doi: 10.1002/ana.25933.
    >> Share

  37. COMI G, Bar-Or A, Lassmann H, Uccelli A, et al
    The role of B cells in Multiple Sclerosis and related disorders.
    Ann Neurol. 2020 Oct 9. doi: 10.1002/ana.25927.
    >> Share

    September 2020
  38. VARLEY JA, Andersson M, Grant E, Berretta A, et al
    Absence of neuronal autoantibodies in neuropsychiatric systemic lupus erythematosus.
    Ann Neurol. 2020 Sep 19. doi: 10.1002/ana.25908.
    >> Share

  39. CIOTTI JR, Grebenciucova E, Moss BP, Newsome SD, et al
    Multiple Sclerosis Disease-Modifying Therapies in the COVID-19 Era.
    Ann Neurol. 2020 Sep 19. doi: 10.1002/ana.25907.
    >> Share

  40. CARCELES-CORDON M, Mannara F, Aguilar E, Castellanos A, et al
    NMDAR Antibodies Alter Dopamine Receptors and Cause Psychotic Behavior in Mice.
    Ann Neurol. 2020;88:603-613.
    >> Share

    August 2020
  41. PALMA JA, Gupta A, Sierra S, Gomes I, et al
    Autoantibodies blocking M3 muscarinic receptors cause postganglionic cholinergic dysautonomia.
    Ann Neurol. 2020 Aug 24. doi: 10.1002/ana.25882.
    >> Share

  42. MAGGI P, Sati P, Nair G, Cortese ICM, et al
    PARAMAGNETIC RIM LESIONS ARE SPECIFIC TO MULTIPLE SCLEROSIS: AN INTERNATIONAL MULTICENTER 3T MRI STUDY.
    Ann Neurol. 2020 Aug 15. doi: 10.1002/ana.25877.
    >> Share

  43. LANDA J, Gaig C, Planaguma J, Saiz A, et al
    Effects of IgLON5 antibodies on neuronal cytoskeleton: a link between autoimmunity and neurodegeneration.
    Ann Neurol. 2020 Aug 2. doi: 10.1002/ana.25857.
    >> Share

  44. PETZOLD A, Coric D, Balk LJ, Hamann S, et al
    Longitudinal Development of Peripapillary Hyper-Reflective Ovoid Masslike Structures Suggests a Novel Pathological Pathway in Multiple Sclerosis.
    Ann Neurol. 2020;88:309-319.
    >> Share

    July 2020
  45. KHOURY SJ
    Progressive Multiple Sclerosis.
    Ann Neurol. 2020 Jul 6. doi: 10.1002/ana.25802.
    >> Share

  46. KORALNIK IJ, Tyler KL
    COVID-19: A Global Threat to the Nervous System.
    Ann Neurol. 2020;88:1-11.
    >> Share

  47. KRYSKO KM, Graves JS, Rensel M, Weinstock-Guttman B, et al
    Real-World Effectiveness of Initial Disease-Modifying Therapies in Pediatric Multiple Sclerosis.
    Ann Neurol. 2020;88:42-55.
    >> Share

    June 2020
  48. PETROVA N, Nutma E, Carassiti D, Newman J, et al
    Synaptic loss in the multiple sclerosis spinal cord.
    Ann Neurol. 2020 Jun 30. doi: 10.1002/ana.25835.
    >> Share

  49. RAUSCHENBERGER V, Wardenburg NV, Schaefer N, Ogino K, et al
    GlyR autoantibodies impair receptor function and induce motor dysfunction.
    Ann Neurol. 2020 Jun 26. doi: 10.1002/ana.25832.
    >> Share

  50. FILIPPI M, Preziosa P, Langdon D, Lassmann H, et al
    Identifying Progression In Multiple Sclerosis: New Perspectives.
    Ann Neurol. 2020 Jun 7. doi: 10.1002/ana.25808.
    >> Share

  51. LEBRUN-FRENAY C, Kantarci O, Siva A, Sormani MP, et al
    Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event.
    Ann Neurol. 2020 Jun 4. doi: 10.1002/ana.25799.
    >> Share

    May 2020
  52. MAGLIOZZI R, Scalfari A, Pisani AI, Ziccardi S, et al
    The CSF profile linked to cortical damage predicts Multiple Sclerosis activity.
    Ann Neurol. 2020 May 17. doi: 10.1002/ana.25786.
    >> Share

  53. AMOR S, Baker D, Khoury SJ, Schmierer K, et al
    SARS-CoV-2 and Multiple Sclerosis: Not all immune depleting DMTs are equal or bad.
    Ann Neurol. 2020 May 8. doi: 10.1002/ana.25770.
    >> Share

  54. MATIAS-GUIU JA, Cabrera-Martin MN, Pytel V, Montero P, et al
    Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage.
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25759.
    >> Share

  55. LEE ST, Lim JA, Chu K, Lee SK, et al
    Reply to "Grading the severity of autoimmune encephalitis: When to evaluate?"
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25760.
    >> Share

  56. CAI MT, Zheng Y, Zhang YX
    Grading the severity of autoimmune encephalitis: When to evaluate?
    Ann Neurol. 2020 May 1. doi: 10.1002/ana.25761.
    >> Share

    April 2020
  57. ZEYDAN B, Kantarci K, Kantarci OH
    Reply to "Amyloid PET in Multiple Sclerosis: between amyloid deposition and myelin damage".
    Ann Neurol. 2020 Apr 30. doi: 10.1002/ana.25758.
    >> Share

  58. BARTELS F, Krohn S, Nikolaus M, Johannsen J, et al
    Clinical and MRI Outcome Predictors in Pediatric Anti-NMDA Receptor Encephalitis.
    Ann Neurol. 2020 Apr 21. doi: 10.1002/ana.25754.
    >> Share

  59. DESAI RA, Davies AL, Del Rossi N, Tachrount M, et al
    Nimodipine reduces dysfunction and demyelination in models of multiple sclerosis.
    Ann Neurol. 2020 Apr 15. doi: 10.1002/ana.25749.
    >> Share

  60. MAHAJAN KR, Nakamura K, Cohen JA, Trapp BD, et al
    Intrinsic and extrinsic mechanisms of thalamic pathology in multiple sclerosis.
    Ann Neurol. 2020 Apr 14. doi: 10.1002/ana.25743.
    >> Share

  61. COLE JH, Raffel J, Friede T, Eshaghi A, et al
    Longitudinal assessment of multiple sclerosis with the brain-age paradigm.
    Ann Neurol. 2020 Apr 14. doi: 10.1002/ana.25746.
    >> Share

  62. SOTIRCHOS ES, Caldito NG, Filippatou A, Fitzgerald KC, et al
    Progressive multiple sclerosis is associated with faster and specific retinal layer atrophy.
    Ann Neurol. 2020 Apr 13. doi: 10.1002/ana.25738.
    >> Share

    March 2020
  63. PITSCH J, Kamalizade D, Braun A, Kuehn JC, et al
    Drebrin autoantibodies in patients with seizures and suspected encephalitis.
    Ann Neurol. 2020 Mar 20. doi: 10.1002/ana.25720.
    >> Share

  64. DE MOL CL, Jansen PR, Muetzel RL, Knol MJ, et al
    Polygenic multiple sclerosis risk and population-based childhood brain imaging.
    Ann Neurol. 2020 Mar 12. doi: 10.1002/ana.25717.
    >> Share

  65. RICHIE M, Pleasure S, Hurley J, Goss A, et al
    ANA Investigates: Pioneering Unbiased Diagnostics.
    Ann Neurol. 2020;87:327-328.
    >> Share

    February 2020
  66. OUELLETTE R, Mangeat G, Polyak I, Warntjes M, et al
    Validation of rapid magnetic resonance myelin imaging in multiple sclerosis.
    Ann Neurol. 2020 Feb 14. doi: 10.1002/ana.25705.
    >> Share

  67. ALPING P, Askling J, Burman J, Fink K, et al
    Cancer Risk for Fingolimod, Natalizumab, and Rituximab in MS Patients.
    Ann Neurol. 2020 Feb 13. doi: 10.1002/ana.25701.
    >> Share

  68. MATUTE C, Palma A, Serrano-Regal MP, Maudes E, et al
    NMDA receptor antibodies in autoimmune encephalopathy alter oligodendrocyte function.
    Ann Neurol. 2020 Feb 12. doi: 10.1002/ana.25699.
    >> Share

  69. DALMAU J
    Pregnancy, N-Methyl-D-Aspartate Receptor Antibodies, and Neuropsychiatric Diseases.
    Ann Neurol. 2020;87:324-325.
    >> Share

  70. JUREK B, Chayka M, Kreye J, Koelch M, et al
    Reply to "Pregnancy, N-Methyl-D-Aspartate Receptor Antibodies, and Neuropsychiatric Diseases".
    Ann Neurol. 2020;87:325-326.
    >> Share

    January 2020
  71. OLDONI E, Smets I, Mallants K, Vandebergh M, et al
    CHIT1 at diagnosis reflects long-term multiple sclerosis disease activity.
    Ann Neurol. 2020 Jan 29. doi: 10.1002/ana.25691.
    >> Share

  72. DOBSON R, Jitlal M, Marshall CR, Noyce AJ, et al
    Ethnic and socioeconomic associations with multiple sclerosis risk.
    Ann Neurol. 2020 Jan 23. doi: 10.1002/ana.25688.
    >> Share

  73. ZEYDAN B, Lowe VJ, Reichard RR, Przybelski SA, et al
    Imaging Biomarkers of Alzheimer's Disease in Multiple Sclerosis.
    Ann Neurol. 2020 Jan 22. doi: 10.1002/ana.25684.
    >> Share

  74. KORNAU HC, Kreye J, Stumpf A, Fukata Y, et al
    Human CSF monoclonal LGI1 autoantibodies increase neuronal excitability.
    Ann Neurol. 2020 Jan 3. doi: 10.1002/ana.25666.
    >> Share

    November 2019
  75. DUBEY D, Britton J, McKeon A, Gadoth A, et al
    Randomized Placebo Controlled Trial of IVIG in autoimmune LGI1/CASPR2 epilepsy.
    Ann Neurol. 2019 Nov 28. doi: 10.1002/ana.25655.
    >> Share

  76. CHUNG KK, Altmann D, Barkhof F, Miszkiel K, et al
    A thirty year clinical and MRI observational study of multiple sclerosis and clinically isolated syndromes.
    Ann Neurol. 2019 Nov 6. doi: 10.1002/ana.25637.
    >> Share

  77. PROBSTEL AK, Zamvil SS
    Do maternal anti-N-methyl-D-aspartate receptor antibodies promote development of neuropsychiatric disease in children?
    Ann Neurol. 2019;86:653-655.
    >> Share

    September 2019
  78. KRYSKO KM, Henry RG, Cree BAC, Lin J, et al
    Telomere length is associated with disability progression in multiple sclerosis.
    Ann Neurol. 2019 Sep 4. doi: 10.1002/ana.25592.
    >> Share

    August 2019
  79. MOCCIA M, Prados F, Filippi M, Rocca MA, et al
    Longitudinal spinal cord atrophy in multiple sclerosis using the generalised boundary shift integral.
    Ann Neurol. 2019 Aug 6. doi: 10.1002/ana.25571.
    >> Share

  80. LOONSTRA FC, Verberk IMW, Wijburg MT, Wattjes MP, et al
    Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy.
    Ann Neurol. 2019;86:322-324.
    >> Share

  81. DALLA COSTA G, Martinelli V, Furlan R, Comi G, et al
    Reply to "Serum Neurofilaments as Candidate Biomarkers of Natalizumab Progressive Multifocal Leukoencephalopathy".
    Ann Neurol. 2019;86:324.
    >> Share

    July 2019
  82. JUREK B, Chayka M, Kreye J, Lang K, et al
    Human gestational NMDAR autoantibodies impair neonatal murine brain function.
    Ann Neurol. 2019 Jul 20. doi: 10.1002/ana.25552.
    >> Share

    June 2019
  83. GIL-PEROTIN S, Alcala C, Perez-Miralles FC, Casanova B, et al
    Silent progression or bout-onset progressive multiple sclerosis?
    Ann Neurol. 2019 Jun 28. doi: 10.1002/ana.25537.
    >> Share

  84. CREE BAC, Hauser SL
    Reply to "Silent progression or bout-onset progressive multiple sclerosis?"
    Ann Neurol. 2019 Jun 28. doi: 10.1002/ana.25536.
    >> Share

  85. MUNGER KL, Hongell K, Cortese M, Aivo J, et al
    Epstein-Barr virus and multiple sclerosis risk in the Finnish Maternity Cohort.
    Ann Neurol. 2019 Jun 21. doi: 10.1002/ana.25532.
    >> Share

    May 2019
  86. VAN LANGELAAR J, Rijvers L, Janssen M, Wierenga-Wolf AF, et al
    Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis.
    Ann Neurol. 2019 May 28. doi: 10.1002/ana.25508.
    >> Share

  87. LIM JA, Lee ST, Chu K, Lee SK, et al
    Reply to "Grading the severity of autoimmune encephalitis: advances and pitfalls".
    Ann Neurol. 2019 May 2. doi: 10.1002/ana.25497.
    >> Share

  88. SPAGNI G, Iorio R
    Grading the severity of autoimmune encephalitis: advances and pitfalls.
    Ann Neurol. 2019 May 2. doi: 10.1002/ana.25496.
    >> Share

  89. NOLAN-KENNEY RC, Liu M, Akhand O, Calabresi PA, et al
    Optimal intereye difference thresholds by optical coherence tomography in multiple sclerosis: An international study.
    Ann Neurol. 2019;85:618-629.
    >> Share

  90. WENKE NK, Kreye J, Andrzejak E, van Casteren A, et al
    N-methyl-D-aspartate receptor dysfunction by unmutated human antibodies against the NR1 subunit.
    Ann Neurol. 2019;85:771-776.
    >> Share

    March 2019
  91. AKTAS O, Hartung HP
    CSI: Multiple sclerosis. Tracing optic nerve involvement by standardized optical coherence tomography.
    Ann Neurol. 2019 Mar 22. doi: 10.1002/ana.25471.
    >> Share

  92. CREE BAC, Hollenbach JA, Bove R, Kirkish G, et al
    Silent Progression in Disease Activity-Free Relapsing Multiple Sclerosis.
    Ann Neurol. 2019 Mar 9. doi: 10.1002/ana.25463.
    >> Share

  93. THALER FS, Thaller AL, Biljecki M, Schuh E, et al
    Abundant glutamic acid decarboxylase (GAD)-reactive B cells in gad-antibody-associated neurological disorders.
    Ann Neurol. 2019;85:448-454.
    >> Share

    February 2019
  94. DALLA COSTA G, Martinelli V, Moiola L, Sangalli F, et al
    Serum neurofilaments increase at PML onset in natalizumab-treated MS patients.
    Ann Neurol. 2019 Feb 13. doi: 10.1002/ana.25437.
    >> Share

  95. FADDA G, Brown RA, Magliozzi R, Aubert-Broche B, et al
    A surface-in gradient of thalamic damage evolves in pediatric multiple sclerosis.
    Ann Neurol. 2019 Feb 4. doi: 10.1002/ana.25429.
    >> Share

    January 2019
  96. LIM JA, Lee ST, Moon J, Jun JS, et al
    Development of the Clinical Assessment Scale in Autoimmune Encephalitis (CASE).
    Ann Neurol. 2019 Jan 24. doi: 10.1002/ana.25421.
    >> Share

  97. BAERT L, Benkhoucha M, Popa N, Ahmed MC, et al
    APRIL-mediated anti-inflammatory response of astrocytes in multiple sclerosis.
    Ann Neurol. 2019 Jan 11. doi: 10.1002/ana.25415.
    >> Share

  98. CACCIAGUERRA L, Meani A, Mesaros S, Radaelli M, et al
    Brain and cord imaging features in neuromyelitis optica spectrum disorders.
    Ann Neurol. 2019 Jan 11. doi: 10.1002/ana.25411.
    >> Share

    October 2018
  99. BEVAN RJ, Evans R, Griffiths L, Watkins LM, et al
    MENINGEAL INFLAMMATION AND CORTICAL DEMYELINATION IN ACUTE MULTIPLE SCLEROSIS.
    Ann Neurol. 2018 Oct 25. doi: 10.1002/ana.25365.
    >> Share

    September 2018
  100. HE D, Zhang H, Xiao J, Zhang X, et al
    Molecular and clinical relationship between live-attenuated Japanese encephalitis vaccination and childhood onset myasthenia gravis.
    Ann Neurol. 2018;84:386-400.
    >> Share

    August 2018
  101. WOLINSKY JS, Montalban X, Hauser SL, Giovannoni G, et al
    Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.
    Ann Neurol. 2018 Aug 29. doi: 10.1002/ana.25313.
    >> Share

  102. SEBASTIAN LOPEZ-CHIRIBOGA A, Klein C, Zekeridou A, McKeon A, et al
    LGI1 and CASPR2 Neurological Autoimmunity in Children.
    Ann Neurol. 2018 Aug 3. doi: 10.1002/ana.25310.
    >> Share

    July 2018
  103. FUJII T, Yamasaki R, Iinuma K, Tsuchimoto D, et al
    A novel autoantibody against plexin D1 in patients with neuropathic pain.
    Ann Neurol. 2018 Jul 16. doi: 10.1002/ana.25279.
    >> Share

    June 2018
  104. JIA X, Madireddy L, Caillier S, Santaniello A, et al
    Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.
    Ann Neurol. 2018 Jun 16. doi: 10.1002/ana.25263.
    >> Share

    May 2018
  105. DISANTO G, Zecca C, MacLachlan S, Sacco R, et al
    Prodromal symptoms of multiple sclerosis in primary care.
    Ann Neurol. 2018 May 8. doi: 10.1002/ana.25247.
    >> Share

    April 2018
  106. TANKOU SK, Regev K, Healy BC, Tjon E, et al
    A probiotic modulates the microbiome and immunity in multiple sclerosis.
    Ann Neurol. 2018 Apr 20. doi: 10.1002/ana.25244.
    >> Share

  107. VOGRIG A, Brigo F, Valente M, Gigli GL, et al
    Epidemiology of autoimmune versus infectious encephalitis.
    Ann Neurol. 2018 Apr 10. doi: 10.1002/ana.25229.
    >> Share

  108. DUBEY D, Pittock SJ, Toledano M, Flanagan EP, et al
    Reply to "Epidemiology of autoimmune versus infectious encephalitis".
    Ann Neurol. 2018 Apr 10. doi: 10.1002/ana.25230.
    >> Share

    March 2018
  109. CRAMER SP, Simonsen HJ, Varatharaj A, Galea I, et al
    Permeability of the blood-brain barrier predicts no evidence of disease activity at two years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis.
    Ann Neurol. 2018 Mar 31. doi: 10.1002/ana.25219.
    >> Share

  110. ANTEL J
    The reality of "ghosts" in authorship of clinical trials in multiple sclerosis.
    Ann Neurol. 2018 Mar 13. doi: 10.1002/ana.25199.
    >> Share

  111. COLES A
    Authorship of phase 3 trials in multiple sclerosis.
    Ann Neurol. 2018 Mar 8. doi: 10.1002/ana.25203.
    >> Share

  112. MAGLIOZZI R, Howell OW, Nicholas R, Cruciani C, et al
    Inflammatory intrathecal profiles and cortical damage in multiple sclerosis.
    Ann Neurol. 2018 Mar 8. doi: 10.1002/ana.25197.
    >> Share

    February 2018
  113. JENDE JME, Groener JB, Oikonomou D, Heiland S, et al
    Diabetic neuropathy differs between type 1 and type 2 diabetes Insights from magnetic resonance neurography.
    Ann Neurol. 2018 Feb 14. doi: 10.1002/ana.25182.
    >> Share

  114. BECK ES, Reich DS
    Brain atrophy in multiple sclerosis: How deep must we go?
    Ann Neurol. 2018;83:208-209.
    >> Share

  115. MAGGI P, Absinta M, Grammatico M, Vuolo L, et al
    Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies.
    Ann Neurol. 2018;83:283-294.
    >> Share

    January 2018
  116. ESHAGHI A, Prados F, Brownlee W, Altmann DR, et al
    Deep grey matter volume loss drives disability worsening in multiple sclerosis.
    Ann Neurol. 2018 Jan 13. doi: 10.1002/ana.25145.
    >> Share

  117. AZEVEDO CJ, Cen SY, Khadka S, Liu S, et al
    Thalamic Atrophy in MS: An MRI Marker of Neurodegeneration Throughout Disease.
    Ann Neurol. 2018 Jan 12. doi: 10.1002/ana.25150.
    >> Share

  118. DUBEY D, Pittock SJ, Kelly CR, McKeon A, et al
    Autoimmune Encephalitis Epidemiology and a comparison to Infectious Encephalitis.
    Ann Neurol. 2018 Jan 2. doi: 10.1002/ana.25131.
    >> Share

    December 2017
  119. GILES DA, Washnock-Schmid JM, Duncker PC, Dahlawi S, et al
    Myeloid cell plasticity in the evolution of central nervous system autoimmunity.
    Ann Neurol. 2017 Dec 28. doi: 10.1002/ana.25128.
    >> Share

  120. GREENFIELD AL, Hauser SL
    B Cell Therapy for Multiple Sclerosis: Entering an Era.
    Ann Neurol. 2017 Dec 15. doi: 10.1002/ana.25119.
    >> Share

  121. PATTERSON KR, Dalmau J, Lancaster E
    Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia.
    Ann Neurol. 2017 Dec 15. doi: 10.1002/ana.25120.
    >> Share

    November 2017
  122. KANAI T, Uzawa A, Sato Y, Suzuki S, et al
    A clinical predictive score for postoperative myasthenic crisis.
    Ann Neurol. 2017;82:841-849.
    >> Share

    October 2017
  123. BARBOUR C, Kosa P, Komori M, Tanigawa M, et al
    Molecular-based diagnosis of Multiple Sclerosis and its progressive stage.
    Ann Neurol. 2017 Oct 23. doi: 10.1002/ana.25083.
    >> Share

  124. AZODI S, Nair G, Enose-Akahata Y, Charlip E, et al
    Imaging Spinal Cord Atrophy in Progressive Myelopathies: HTLV-I Associated Neurologic Disease (HAM/TSP) and Multiple Sclerosis (MS).
    Ann Neurol. 2017 Oct 10. doi: 10.1002/ana.25072.
    >> Share

  125. JENDE JME, Hauck GH, Diem R, Weiler M, et al
    Peripheral nerve involvement in multiple sclerosis Demonstration by magnetic resonance neurography.
    Ann Neurol. 2017 Oct 10. doi: 10.1002/ana.25068.
    >> Share

  126. MAINERO C, Louapre C
    Unravelling cortical pathology in multiple sclerosis using the T1-/T2-weighted ratio?
    Ann Neurol. 2017 Oct 4. doi: 10.1002/ana.25063.
    >> Share

  127. WIJNANDS JMA, Tremlett H
    Concussion may not cause multiple sclerosis.
    Ann Neurol. 2017 Oct 4. doi: 10.1002/ana.25061.
    >> Share

  128. MONTGOMERY S, Hiyoshi A, Burkill S, Alfredsson L, et al
    Reply to: Concussion may not cause multiple sclerosis.
    Ann Neurol. 2017 Oct 4. doi: 10.1002/ana.25062.
    >> Share

    September 2017
  129. FITZGERALD KC, Munger KL, Ascherio A
    Reply to "Stratified analyses are necessary to verify the influence of salt intake in multiple sclerosis".
    Ann Neurol. 2017 Sep 29. doi: 10.1002/ana.25055.
    >> Share

  130. ZAHEDNASAB H, Harirchian MH, Karampoor S, Keyvani H, et al
    MMP-9 as a biomarker of PML development in MS patients receiving Natalizumab.
    Ann Neurol. 2017 Sep 4. doi: 10.1002/ana.25037.
    >> Share

  131. FISSOLO N, Pignolet B, Brassat D, Comabella M, et al
    Reply: MMP-9 as a biomarker of PML development in MS patients receiving Natalizumab.
    Ann Neurol. 2017 Sep 4. doi: 10.1002/ana.25039.
    >> Share

  132. MONTGOMERY S, Hiyoshi A, Burkill S, Alfredsson L, et al
    Concussion in adolescence and risk of multiple sclerosis.
    Ann Neurol. 2017 Sep 4. doi: 10.1002/ana.25036.
    >> Share

    August 2017
  133. NAKAMURA K, Chen JT, Ontaneda D, Fox RJ, et al
    T1-/T2-weighted ratio differs in demyelinated cortex of multiple sclerosis.
    Ann Neurol. 2017 Aug 18. doi: 10.1002/ana.25019.
    >> Share

  134. RIGHART R, Biberacher V, Jonkman LE, Klaver R, et al
    Cortical pathology in MS detected by the T1/T2-weighted ratio from routine MRI.
    Ann Neurol. 2017 Aug 18. doi: 10.1002/ana.25020.
    >> Share

  135. DALAKAS MC, Rakocevic G, Dambrosia JM, Alexopoulos H, et al
    A double-blind, placebo-controlled study of rituximab in patients with stiff person syndrome.
    Ann Neurol. 2017;82:271-277.
    >> Share

    July 2017
  136. YATES RL, Esiri MM, Palace J, Jacobs B, et al
    Fibrin(ogen) and neurodegeneration in the progressive multiple sclerosis cortex.
    Ann Neurol. 2017 Jul 18. doi: 10.1002/ana.24997.
    >> Share

  137. FISSOLO N, Pignolet B, Matute-Blanch C, Trivino JC, et al
    MMP9 is decreased in natalizumab-treated MS patients at risk for PML.
    Ann Neurol. 2017 Jul 6. doi: 10.1002/ana.24987.
    >> Share

    May 2017
  138. FITZGERALD KC, Munger KL, Hartung HP, Freedman MS, et al
    Sodium intake and multiple sclerosis activity and progression in BENEFIT.
    Ann Neurol. 2017 May 26. doi: 10.1002/ana.24965.
    >> Share

  139. DISANTO G, Barro C, Benkert P, Naegelin Y, et al
    Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis.
    Ann Neurol. 2017 May 16. doi: 10.1002/ana.24954.
    >> Share

  140. CUI QL, Khan D, Rone M, Rao V, et al
    Sublethal oligodendrocyte injury: A reversible condition in multiple sclerosis?
    Ann Neurol. 2017 May 3. doi: 10.1002/ana.24944.
    >> Share

  141. IAFFALDANO P, Simone M, Lucisano G, Ghezzi A, et al
    Prognostic indicators in pediatric clinically isolated syndrome.
    Ann Neurol. 2017;81:729-739.
    >> Share

    April 2017
  142. ANDRODIAS G, Bernard E, Biotti D, Collongues N, et al
    Multiple sclerosis broke my heart.
    Ann Neurol. 2017 Apr 24. doi: 10.1002/ana.24935.
    >> Share

  143. SELMAJ I, Cichalewska M, Namiecinska M, Galazka G, et al
    Global Exosome Transcriptome Profiling Reveals Biomarkers for Multiple Sclerosis.
    Ann Neurol. 2017 Apr 15. doi: 10.1002/ana.24931.
    >> Share

    March 2017
  144. TAWARA N, Yamashita S, Zhang X, Korogi M, et al
    Pathomechanisms of anti-cN1A autoantibodies in sporadic inclusion body myositis.
    Ann Neurol. 2017 Mar 20. doi: 10.1002/ana.24919.
    >> Share

  145. TREMLETT H, Bauer KC, Appel-Cresswell S, Finlay BB, et al
    The gut microbiome in human neurological disease: A review.
    Ann Neurol. 2017;81:369-382.
    >> Share

    February 2017
  146. KIM TJ, Lee ST, Moon J, Sunwoo JS, et al
    Anti-LGI1 encephalitis is associated with unique HLA subtypes.
    Ann Neurol. 2017;81:183-192.
    >> Share

    December 2016
  147. HERRANZ E, Hooker JM, Izquierdo-Garcia D, Loggia ML, et al
    11 C-PBR28 increase in multiple sclerosis reflects neuroinflammation.
    Ann Neurol. 2016 Dec 29. doi: 10.1002/ana.24865.
    >> Share

  148. RAFFEL J, Sridharan S, Nicholas R
    [11 C]PBR-28 PET in multiple sclerosis: Neuroinflammation or otherwise?
    Ann Neurol. 2016 Dec 26. doi: 10.1002/ana.24853.
    >> Share

    July 2016
  149. WHITE MK, Wollebo HS, Beckham JD, Tyler KL, et al
    Zika virus: An emergent neuropathological agent.
    Ann Neurol. 2016 Jul 27. doi: 10.1002/ana.24748.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016